SHSarah Hamidi

Sarah Hamidi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Hamidi has a total of 157 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical features and outcomes of MEN2A with RET codon 634 pathogenic variants

    by Sarah Hamidi, Steven G Waguespack, Naifa L Busaidy, Paul H Graham, Mouhammed A Habra, Nancy D Perrier, Steven I Sherman, Catherine B Skefos, Julie Ann Sosa, Anita K Ying, et al.

    Background: Germline RET codon 634 pathogenic variants (PVs) are at high-risk for early-onset medullary thyroid carcinoma (MTC), but prior reports suggest that RET p.C634R PV may confer a more aggressive phenotype. Methods: We compared MEN2A phenotype and MTC outcomes with germline RET p.C634R vs other RET p.C634X PVs. We conducted a retrospective single-center cohort study of patients harboring a germline RET p.C634 PV, enrolled in the MTC Collaborative Registry (MTCCoRe) and seen at least once between May 2012 and May 2024. Results: One hundred and thirty-five patients included: p.C634R (n = 60) and other p.C634X variants (n = 75). The p.C634R PV was associated with higher penetrance of pheochromocytoma (PHEO) (67% vs 37%, P < .001) and primary hyperparathyroidism (PHPT) (30% vs 15%, P = .036). Prevalence of MTC (87% vs 80%, P = .362), cutaneous lichen amyloidosis (17% vs 9% P = .296), and median age at initial thyroidectomy (18 vs 20 years, P = .479) did not differ significantly between groups. Medullary thyroid carcinoma characteristics, including stage, multifocality, extrathyroidal extension, vascular invasion, lymph node metastases, and distant metastases, were comparable. There were no significant differences in disease-free survival, overall survival, or distant metastasis-free survival for MTC. Disease status at last follow-up also was similar between p.C634R and other p.C634X PVs: no evidence of disease in 43% vs 62% (P = .059), biochemical evidence of disease in 25% vs 17% (P = .226), and structural evidence of disease in 27% vs 20% (P = .298). Conclusion: In this large single-center cohort, germline RET p.C634R was associated with a higher penetrance of PHEO and PHPT but did not increase MTC aggressiveness or worsen clinical outcomes compared with other RET p.C634 PVs.

  • Open Access

    Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial

    by Maria E. Cabanillas, Naifa L. Busaidy, Mark Zafereo, Priyanka C. Iyer, Jennifer R. Wang, Sarah Hamidi, Renata Ferrarotto, Suyu Liu, Gary B. Gunn, Michael Spiotto, et al.

  • Revised Thyroid Differentiation Score for Risk Stratification in Papillary Thyroid Carcinoma

    by Vicente R. Marczyk, Chia Chin Wu, Sarah Hamidi, Sophie Li, Matthew A. Loberg, Meghan Martin, Michelle D. Williams, Sayed Mohsen Hosseini, Steven Waguespack, Mimi Hu, et al.

    PURPOSE: Loss of thyroid differentiation underlies the aggressive behavior of a subset of papillary thyroid carcinomas (PTCs). The Thyroid Differentiation Score (TDS), introduced by The Cancer Genome Atlas (TCGA), quantifies tumor differentiation but has limited reproducibility and clinical applicability. We developed and validated a revised score (xTDS) that enables reproducible assessment of tumor differentiation with prognostic relevance across cohorts. METHODS: We analyzed RNA sequencing data from 570 patients with PTC across three independent cohorts: a discovery cohort from the MD Anderson Cancer Center (n = 111) and two external validation cohorts from Vanderbilt University (n = 69) and TCGA (n = 390). xTDS was evaluated for correlation with the original TDS, association with oncogenic drivers, and prognostic value for disease-specific survival (DSS) and progression-free survival (PFS). RESULTS: xTDS showed near-perfect correlation with the original TDS (Spearman ρ = 0.98) and recapitulated known biological patterns, with BRAF V600E–driven tumors exhibiting the lowest differentiation scores and RAS -driven tumors the highest across all cohorts ( P < .001). Low xTDS was associated with worse DSS in the MD Anderson ( P < .001) and Vanderbilt ( P = .005) cohorts and showed a similar numerical trend in TCGA, without statistical significance because of limited events. Low xTDS was consistently associated with worse PFS across all three cohorts ( P = .048, <0.001, and 0.007, respectively). CONCLUSION: xTDS is a reproducible measure of thyroid differentiation that preserves the biological and prognostic relevance of the original TDS while overcoming technical constraints affecting reproducibility.


  • Open Access

    Supplementary Tables S1-S31 from PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma

    by Sophie Li, Chia-Chin Wu, Vicente R. Marczyk, Matthew A. Loberg, Aatish Thennavan, Maxime Tarabichi, Li Xu, Ying C. Henderson, Meghan E. Martin, Tuan M. Tran, et al.

    Supplemental Table 1. Single-nucleus RNA sequencing sample information Supplemental Table 2. Canonical gene markers for cell type annotation Supplemental Table 3. PRECISE genes and their direct interactors Supplemental Table 4. List of all the genes from bulk RNA sequencing used for ranking Supplemental Table 5. Genes used calculate the MAP score Supplemental Table 6. PRECISE genes Supplemental Table 7. Gene enrichment overlap analysis for PRECISE gene set Supplemental Table 8. Gene enrichment overlap analysis for PRECISE genes and direct interactors Supplemental Table 9. Gene set enrichment analysis of PRECISE and network-associated genes Supplemental Table 10. Censoring rates across the three cohorts for progression-free and disease-specific survival Supplemental Table 11. Spearman's correlation analyses between PRECISE score and tumor purity Supplemental Table 12. Multivariate Cox proportional hazards with all covariates for progression-free survival in the MDACC, VUMC, and TCGA cohorts. Supplemental Table 13. Univariate and multivariate Cox proportional hazards models using Firth’s penalized likelihood for progression-free survival in the MDACC, VUMC, and TCGA cohorts Supplemental Table 14. Jackknife pseudo-value regression analysis of 2- and 5-year restricted mean survival time for progression-free survival Supplemental Table 15. Univariate and multivariate Coxproportional hazards models for disease-specific survival in the MDACC, VUMC, and TCGA cohorts. Supplemental Table 16. Multivariate Cox proportional hazards models for disease-specific survival in the MDACC cohort. Supplemental Table 17. Univariate and multivariate Cox proportional hazards models using Firth's penalized likelihood for disease-specific survival in the MDACC, VUMC, and TCGA cohorts Supplemental Table 18. Jackknife pseudo-value regression analysis of 2- and 5-year restricted mean survival time for disease-free survival Supplemental Table 19. Performance of predictive models for progression-free survival in the MDACC, VUMC, and TCGA cohorts Supplemental Table 20. Predictive models for progression-free survival in the MDACC, VUMC, and TCGA cohorts Supplemental Table 21. Prediction models for disease-specific survival in the MDACC cohort Supplemental Table 22. Univariate Cox proportional hazards models for progression-free survival in T stage-stratified subgroups Supplemental Table 23. Univariate Cox proportional hazards models for progression-free survival in BRAF-stratified subgroups Supplemental Table 24. Univariate Cox proportional hazards models for progression-free survival in BRAF-stratified subgroups with additional BRAF wild-type stratification Supplemental Table 25. Univariate Cox proportional hazards analysis stratified by median ESTIMATE score and fibrosis score Supplemental Table 26. Multivariate Cox-proportional hazards models with TERT promotor mutation status for progression-free survival and disease-specific survival in the MDACC cohort Supplemental Table 27. Spearman correlation of PRECISE with TDS and MAP scores Supplemental Table 28. Univariate and multivariate Cox proportional hazards models with Firth's penalized likelihood for PRECISE score and TDS in progression-free survival Supplemental Table 29. Univariate and multivariate Cox proportional hazards models with Firth's penalized likelihood for PRECISE score and TDS in disease-specific survival Supplemental Table 30. Multivariate Cox proportional hazards models with Firth's penalized likelihood for PRECISE score and MAP score Supplemental Table 31. Clinicopathologic characteristics of the fine needle aspiration cohort (n = 33).

  • Open Access

    Supplementary Figure S3 from PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma

    by Sophie Li, Chia-Chin Wu, Vicente R. Marczyk, Matthew A. Loberg, Aatish Thennavan, Maxime Tarabichi, Li Xu, Ying C. Henderson, Meghan E. Martin, Tuan M. Tran, et al.

    Network of PRECISE genes (red nodes) and their direct interactors (blue).

  • Open Access

    Supplementary Figure S4 from PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma

    by Sophie Li, Chia-Chin Wu, Vicente R. Marczyk, Matthew A. Loberg, Aatish Thennavan, Maxime Tarabichi, Li Xu, Ying C. Henderson, Meghan E. Martin, Tuan M. Tran, et al.

    Receiver operating characteristic (ROC) curves for 177 genes cited in at least 3 publications related to aggressive PTC and 328 genes from KEGG cancer pathways.

  • Open Access

    Supplementary Figure S6 from PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma

    by Sophie Li, Chia-Chin Wu, Vicente R. Marczyk, Matthew A. Loberg, Aatish Thennavan, Maxime Tarabichi, Li Xu, Ying C. Henderson, Meghan E. Martin, Tuan M. Tran, et al.

    Heatmap of gene-gene correlations for the PRECISE gene signature in the (A) MDACC, (B) VUMC, and (C) TCGA cohorts.

  • Open Access

    Supplementary Figure S8 from PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma

    by Sophie Li, Chia-Chin Wu, Vicente R. Marczyk, Matthew A. Loberg, Aatish Thennavan, Maxime Tarabichi, Li Xu, Ying C. Henderson, Meghan E. Martin, Tuan M. Tran, et al.

    Distribution of PRECISE scores based on (A) overall stage and (B) driver mutation status.

  • Open Access

    Data from PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma

    by Sophie Li, Chia-Chin Wu, Vicente R. Marczyk, Matthew A. Loberg, Aatish Thennavan, Maxime Tarabichi, Li Xu, Ying C. Henderson, Meghan E. Martin, Tuan M. Tran, et al.

    Purpose:Papillary thyroid carcinoma (PTC) exhibits heterogeneous behavior, underscoring the need for effective biomarkers and improved risk stratification methods. We developed a thyrocyte-derived gene signature, Prognostic RNA Expression Cell-specific Integrated Signature (PRECISE), using single-cell RNA sequencing (scRNA-seq) and single-nucleus RNA sequencing (snRNA-seq) and evaluated its prognostic utility across cohorts.Experimental Design:PRECISE was developed using a discovery cohort of patients with PTC [MD Anderson Cancer Center (MDACC), n = 109, median follow-up = 14 years]. Within the cohort, 11 PTC tumors and 4 normal thyroid samples were successfully sequenced using snRNA-seq. Differentially expressed genes were integrated with previously identified thyrocyte-associated genes from scRNA-seq. Prognostic significance was assessed using bulk RNA-seq in the discovery cohort and validated in two additional cohorts [Vanderbilt University Medical Center (VUMC), n = 65; The Cancer Genome Atlas (TCGA), n = 370]. A rank-based single-sample method was used for score calculation. Associations between PRECISE and progression-free survival (PFS) and disease-specific survival (DSS) were evaluated using multivariate Cox models, and predictive models were compared using Harrell’s C-statistic and likelihood ratio tests.Results:PRECISE is comprised of 41 epithelial genes downregulated in PTC tumor cells. Higher PRECISE was significantly associated with shorter PFS across all three cohorts [MDACC: hazard ratio (HR) = 1.64, P = 0.002; VUMC: HR = 2.54, P < 0.001; TCGA: HR = 1.63, P = 0.012] and remained significant after tumor–node–metastasis stage adjustment in two cohorts with ≥5 years of follow-up [MDACC adjusted HR (aHR) = 1.42, P = 0.038; VUMC aHR = 2.12, P = 0.024]. PRECISE was also associated with DSS in these cohorts (MDACC: HR = 4.16, P < 0.001; VUMC: HR = 2.23, P = 0.010). Incorporating PRECISE significantly improved predictive performance for PFS and DSS beyond stage-based models.Conclusions:PRECISE is a thyroid epithelial gene signature with independent prognostic value in PTC.

  • Open Access

    Supplementary Figure S11 from PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma

    by Sophie Li, Chia-Chin Wu, Vicente R. Marczyk, Matthew A. Loberg, Aatish Thennavan, Maxime Tarabichi, Li Xu, Ying C. Henderson, Meghan E. Martin, Tuan M. Tran, et al.

    Kaplan-Meier analysis of low- vs high-risk PRECISE score in (A-C) progression-free survival and (D-F) disease-specific survival in the MDACC, VUMC, and TCGA cohorts, respectively.